Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up

L. Cashin-Hemphill, W. J. Mack, J. M. Pogoda, M. E. Sanmarco, S. P. Azen and D. H. Blankenhorn
Department of Medicine, University of Southern California, Los Angeles.

The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol-niacin therapy in 162 subjects. Two-year results (CLAS-I) showed decreased atherosclerosis progression and increased regression. We now describe a subgroup of 103 subjects treated for 4 years (CLAS-II). Changes in blood lipid, lipoprotein-cholesterol, and apolipoprotein levels were maintained, and at 4 years significantly more drug-treated subjects demonstrated nonprogression (52% drug- vs 15% placebo-treated) and regression (18% drug- vs 6% placebo-treated) in native coronary artery lesions. Significantly fewer drug-treated subjects developed new lesions in native coronary arteries (14% drug- vs 40% placebo-treated) and bypass grafts (16% drug- vs 38% placebo-treated). These results confirm CLAS-I findings and indicate that regression can continue for 4 years. They reaffirm the need for early initiation of vigorous long-term lipid lowering therapy in coronary bypass subjects.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Lipid Management to Reduce Cardiovascular Risk: A New Strategy Is Required
Superko and King
Circulation 2008;117:560-568.
FULL TEXT  

High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh et al.
JAMA 2007;298:786-798.
ABSTRACT | FULL TEXT  

The Unique Character of Cardiovascular Disease in Chronic Kidney Disease and Its Implications for Treatment with Lipid-Lowering Drugs
Nogueira and Weir
CJASN 2007;2:766-785.
ABSTRACT | FULL TEXT  

Comparison of Intravascular Ultrasound and Quantitative Coronary Angiography for the Assessment of Coronary Artery Disease Progression
Berry et al.
Circulation 2007;115:1851-1857.
ABSTRACT | FULL TEXT  

Reducing risk by raising HDL-cholesterol: the evidence
Drexel
Eur Heart J Suppl 2006;8:F23-F29.
ABSTRACT | FULL TEXT  

Niaspan(R) in the management of dyslipidaemia: the evidence
Brown
Eur Heart J Suppl 2006;8:F60-F67.
ABSTRACT | FULL TEXT  

Maximizing coronary disease risk reduction using nicotinic acid combined with LDL-lowering therapy
Brown
Eur Heart J Suppl 2005;7:F34-F40.
ABSTRACT | FULL TEXT  

Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia
Chapman
Eur Heart J Suppl 2005;7:F56-F62.
ABSTRACT | FULL TEXT  

Statin Initiation Following Coronary Artery Bypass Grafting: Outcome of a Hospital Discharge Protocol
Khanderia et al.
Chest 2005;127:455-463.
ABSTRACT | FULL TEXT  

Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery: A review of randomized controlled trials
Okrainec et al.
J Am Coll Cardiol 2005;45:177-184.
ABSTRACT | FULL TEXT  

Modern intervention strategies for managing dyslipidaemia: the case for combination therapy
Drexel
British Journal of Diabetes & Vascular Disease 2005;5:S17-S23.
ABSTRACT  

Addressing Cardiovascular Disease in Women: Focus on Dyslipidemia
Meagher
J Am Board Fam Med 2004;17:424-437.
ABSTRACT | FULL TEXT  

New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders
McKenney
Arch Intern Med 2004;164:697-705.
ABSTRACT | FULL TEXT  

Statins in coronary bypass surgery: rationale and clinical use
Werba et al.
Ann. Thorac. Surg. 2003;76:2132-2140.
ABSTRACT | FULL TEXT  

Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials
Friday
Exp. Biol. Med. 2003;228:769-778.
ABSTRACT | FULL TEXT  

Understanding the pathophysiology of the arterial wall: which method should we choose? Intra-vascular ultrasound
DeFranco
Eur Heart J Suppl 2002;4:F29-F40.
ABSTRACT  

Coronary plaque regression: role of low density lipoprotein-apheresis
Barter
J Am Coll Cardiol 2002;40:228-230.
FULL TEXT  

Prognostic factors for atherosclerosis progression in saphenous vein grafts: The postcoronary artery bypass graft (post-CABG) trial
Domanski et al.
J Am Coll Cardiol 2000;36:1877-1883.
ABSTRACT | FULL TEXT  

Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias
Fodor et al.
CMAJ 2000;162:1441-1447.
FULL TEXT  

Coronary artery bypass surgery with arterial grafts in familial hypercholesterolemia
Kawasuji et al.
J. Thorac. Cardiovasc. Surg. 2000;119:1008-1013.
ABSTRACT | FULL TEXT  

Commentary
Tector and McDonald
J. Thorac. Cardiovasc. Surg. 2000;119:1013-1014.
FULL TEXT  

Cardiovascular risk in women: the cardiologist's perspective
EDMUNDS and LIP
QJM 2000;93:135-145.
FULL TEXT  

Colesevelam Hydrochloride (Cholestagel): A New, Potent Bile Acid Sequestrant Associated With a Low Incidence of Gastrointestinal Side Effects
Davidson et al.
Arch Intern Med 1999;159:1893-1900.
ABSTRACT | FULL TEXT  

Strategies to achieve coronary arterial plaque stabilization
Rabbani and Topol
Cardiovasc Res 1999;41:402-417.
ABSTRACT | FULL TEXT  

Aortocoronary Saphenous Vein Graft Disease : Pathogenesis, Predisposition, and Prevention
Motwani and Topol
Circulation 1998;97:916-931.
ABSTRACT | FULL TEXT  

Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol
Frick et al.
Circulation 1997;96:2137-2143.
ABSTRACT | FULL TEXT  

Hypobetalipoproteinemia Is Associated With Low Levels of Hemostatic Risk Factors in the Framingham Offspring Population
Welty et al.
Circulation 1997;95:825-830.
ABSTRACT | FULL TEXT  

Effect of Supplementary Antioxidant Vitamin Intake on Carotid Arterial Wall Intima-Media Thickness in a Controlled Clinical Trial of Cholesterol Lowering
Azen et al.
Circulation 1996;94:2369-2372.
ABSTRACT | FULL TEXT  

LDL-Apheresis Atherosclerosis Regression Study (LAARS) : Effect of Aggressive Versus Conventional Lipid Lowering Treatment on Coronary Atherosclerosis
Kroon et al.
Circulation 1996;93:1826-1835.
ABSTRACT | FULL TEXT  

Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference?
Corson et al.
PERSPECT VASC SURG ENDOVASC THER 1996;9:75-94.
 

Progression of Coronary Artery Disease Predicts Clinical Coronary Events : Long-term Follow-up From the Cholesterol Lowering Atherosclerosis Study
Azen et al.
Circulation 1996;93:34-41.
ABSTRACT | FULL TEXT  

Lipid Lowering, Regression, and Coronary Events : A Review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council Meeting
Gotto
Circulation 1995;92:646-656.
FULL TEXT  

CHOLESTEROL REDUCTION AND REGRESSION OF CORONARY DISEASE
JWatch General 1991;1991:3-3.
FULL TEXT